Physician profile
Kamel M Kamel
NPI 1316379712
$2,193.95
in general payments reported to CMS, 2019-2025
21 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $278 · 2021: $404 · 2022: $187 · 2023: $206 · 2024: $523 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $545.09 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $376.53 | 2020-2023 | Rybelsus |
| Pfizer INC. | $233.65 | 2019-2025 | |
| Lilly USA, LLC | $170.74 | 2022-2025 | Zepbound, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $153.99 | 2019-2025 | Cobenfy |
| Phathom Pharmaceuticals, INC. | $137.77 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.74 | 2019-2024 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $109.35 | 2024 | Ultomiris |
| Dexcom, INC. | $62.76 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $58.26 | 2022-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $25.99 | 2023 | Osteocool Rf Ablation System |
| Boston Scientific Corporation | $24.61 | 2024 | Watchman Flx |
| Glaxosmithkline, LLC. | $23.72 | 2025 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $22.34 | 2024 | Ingrezza |
| Lundbeck LLC | $20.64 | 2023 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20.43 | 2024 | Farxiga |
| Smith+Nephew, INC. | $19.67 | 2024 | Collagenase Santyl, Iodosorb Ointment 40g USA, Regranex |
| Amgen INC. | $19.52 | 2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $19.36 | 2022 | |
| Mimedx Group, INC. | $16.58 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamel Kamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.